Analysts expect Akebia Therapeutics Inc (NASDAQ:AKBA) to post ($0.77) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Akebia Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($1.13). Akebia Therapeutics posted earnings per share of ($0.49) during the same quarter last year, which indicates a negative year-over-year growth rate of 57.1%. The business is scheduled to announce its next earnings results on Wednesday, November 14th.
On average, analysts expect that Akebia Therapeutics will report full-year earnings of ($2.70) per share for the current financial year, with EPS estimates ranging from ($3.41) to ($2.12). For the next financial year, analysts forecast that the company will post earnings of ($2.85) per share, with EPS estimates ranging from ($4.80) to ($1.23). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.09). Akebia Therapeutics had a negative return on equity of 46.95% and a negative net margin of 30.60%. The firm had revenue of $48.79 million during the quarter, compared to the consensus estimate of $48.75 million.
A number of analysts recently issued reports on the company. Zacks Investment Research lowered Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 19th. BidaskClub downgraded shares of Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. HC Wainwright reduced their price target on Akebia Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, June 6th. Finally, Needham & Company LLC cut their target price on Akebia Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Akebia Therapeutics has a consensus rating of “Buy” and an average target price of $18.75.
A number of hedge funds have recently modified their holdings of the business. Landscape Capital Management L.L.C. raised its stake in Akebia Therapeutics by 241.4% during the 1st quarter. Landscape Capital Management L.L.C. now owns 116,416 shares of the biopharmaceutical company’s stock worth $1,109,000 after acquiring an additional 82,315 shares in the last quarter. UBS Group AG boosted its holdings in Akebia Therapeutics by 66.0% during the first quarter. UBS Group AG now owns 192,349 shares of the biopharmaceutical company’s stock worth $1,833,000 after buying an additional 76,480 shares in the last quarter. Sun Life Financial INC purchased a new stake in Akebia Therapeutics during the second quarter worth about $193,000. Virginia Retirement Systems ET AL boosted its holdings in Akebia Therapeutics by 266.5% during the second quarter. Virginia Retirement Systems ET AL now owns 141,100 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 102,600 shares in the last quarter. Finally, CVI Holdings LLC purchased a new stake in Akebia Therapeutics during the first quarter worth about $3,121,000. 75.18% of the stock is owned by institutional investors.
Shares of NASDAQ AKBA opened at $7.44 on Friday. Akebia Therapeutics has a 1-year low of $7.42 and a 1-year high of $20.25. The company has a market cap of $431.83 million, a price-to-earnings ratio of -4.20 and a beta of 0.98.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Further Reading: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.